Methylenetetrahydrofolate reductase C677T genotypes and clinical outcome following hematopoietic cell transplant

Experimental and Clinical Transplantation

Volumn 5, Issue 2, 2007, Pages 693-697

  Azarpira, Negar ^a   Ramzi, Mani ^a   Aghdaie, Mahdokht Hossein ^a   Daraie, Masumeh ^a   Geramizadeh, Bita ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Graft versus host disease; Methotrexate; Polymorphism; Prophylaxis; Transplantation

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DONOR; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GRANULOCYTE; HAPLOTYPE; HLA MATCHING; HUMAN; LYMPHOMA; MALE; METASTASIS; NORMAL VALUE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RECIPIENT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SHORT COURSE THERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; THALASSEMIA; THROMBOCYTE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; COHORT STUDIES; CYCLOSPORINE; FEMALE; GENOTYPE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 38549089610     PISSN: 13040855     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314(12):729-735.
2. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998; 102(2):322-328.
3. Fridland A. Effect of methotrexate on deoxyribonucleotide pools and DNA synthesis in human lymphocytic cells. Cancer Res. 1974;34(8):1883-1888.
4. Budzik GP, Colletti LM, Faltynek CR. Effects of methotrexate on nucleotide pools in normal human T cells and the CEM T cell line. Life Sci. 2000;66(23):2297-2307.
5. Friso S, Choi SW, Girelli D, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc Natl Acad Sci U S A. 2002;99(8):5606-5611.
6. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetra-hydrofolate reductase. Nat Genet. 1995;10(1):111-113.
7. Tishler M, Caspi D, Fishel B, Yaron M. The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients. Arthritis. Rheum. 1988 Jul;31(7):906-908.
8. Joyce DA, Will RK, Hoffman DM, Laing B, Blackbourn SJ. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis. 1991;50(12):913-914.
9. Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (second of two parts). N Engl J Med. 1975;292(17):895-902.
10. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974; 18(4):295-304.
11. Kowa H, Yasui K, Takeshima T, Urakami K, Sakai F, Nakashima K. The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. Am J Med Genet. 2000;96(6):762-764.
12. van Ede AE, Laan RF, Blom HJ, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum. 2001;44(11): 2525-2530.
13. Garcia-Tevijano ER, Berasain C, Rodriguez JA, et al. Hyperhomocysteinemia in liver cirrhosis: mechanisms and role in vascular and hepatic fibrosis. Hypertension. 2001;38(5):1217-1221.
14. Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics. 2002;12(3):183-190.
15. Winkelmayer WC, Kramar R, Sunder-Plassmann G, Födinger M. Effects of single-nucleotide polymorphisms in MTHFR and MTRR on mortality and allograft loss in kidney transplant recipients. Kidney Int. 2005;68(6):2857-2862.
16. Kalayoglu-Besisik S, Caliskan Y, Sargin D, Gurses N, Ozbek U. Methylenetetrahydrofolate reductase C677T polymorphism and toxicity in allogeneic hematopoietic cell transplantation. Transplantation. 2003 27;76(12):1775-1777.
17. Kim I, Lee KH, Kim JH, et al. Polymorphisms of the methylenetetrahydrofolate reductase gene and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2007;86(1):41-48.
18. Murphy N, Diviney M, Szer J, et al. Donor methylenetetrahydrofolate reductase genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant. 2006;37(8):773-779.
19. Robien K, Bigler J, Yasui Y, et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes and risk of acute graft-versus-host disease following hematopoietic cell transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2006;12(9):973-980.
20. Robien K, Ulrich CM, Bigler J, et al. Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia. Clin Cancer Res. 2004; 10(22):7592-7598.
21. Pihusch M, Lohse P, Reitberger J, et al. Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2004;78(6):911-918.